BUSINESS BASIS
Axiogenesis AG is a small-scale capital company in the sense of 267 paragraph 1 of the HGB (German commercial code). It is drawn up its annual financial statement according to the guidelines for large-scale capital companies in line with section 267 paragraph 3 of the HGB and supplements them with a voluntary management report.
Purpose of Company
Development, acquisition and economic utilisation of processes in the field of applied stem cell technology.
Shareholders
| Dürckheim Investment Ltd | |
| Gerlach Beteiligungs GmbH | |
| Dr. Heribert Bohlen | |
| Bohlen GmbH | |
| Dr. Bernd Fleischmann | |
| Fronhoff Beteiligungs GmbH | |
| Kollar & Partner FinanzConsult GmbH | |
| FHC Assets Ltd. | |
| KfW Bankengruppe | |
| Beteiligungsgesellschaft Alstertor mbH | |
| Frankfurt-Trust Investment-Gesellschaft mbH |
|
| V+ GmbH & Co. Fonds 2 KG | |
| Free Float |
Annual General Meeting 2010 (PDF)
